Skip to main content

Table 4 Variables associated with the combined clinical endpoint of RBV dose reduction, transfusion of erythrocyte concentrates, or administration of epoetin-α

From: Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy

  Univariate analysis Multivariate analysis
Characteristics Odds ratio [95% CI] Pvalue Odds ratio [95% CI] Pvalue
EPO rs1617640 (GG vs. TT/TG) 4.19 [2.31 – 7.59] < 0.001 4.14 [2.20 – 7.82] < 0.001
Sex (female vs. male) 0.45 [0.24 – 0.83] 0.013 0.41 [0.21 – 0.80] 0.003
Baseline Hb (g/dl) 0.87 [0.70 – 1.09] 0.24 0.83 [0.65 – 1.07] 0.168
RBV start dose* 1.21 [1.04 – 1.40] 0.012 1.18 [1.01 – 1.39] 0.036
  1. Abbreviations: EPO erythropoietin, ITPA inosine triphosphatase, RBV ribavirin, CI confidence interval. *RBV starting dose is coded as a continuous variable with an intercept at 800 and an increase of 1 in the model corresponding to 100 mg increase of the actual dose.